NATCOPHARM: FY26 revenue hit INR 43,759 Mn, with strong export growth and strategic R&D investments
Less than 1 min read
FY26 revenue reached INR 43,759 Mn, driven by export formulations and new launches in India and the US. Q4FY26 profit after tax was INR 2,690 Mn, aided by a one-time tax benefit. Strategic acquisitions and investments in advanced therapies support future growth.
Original document: NATCO Pharma Limited [NATCOPHARM] Slides Release — May. 29 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr